Pasithea Therapeutics (KTTA) Cash from Investing Activities (2021 - 2023)

Pasithea Therapeutics' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at $54536.0 for Q4 2023.

• In Q4 2023, Cash from Investing Activities rose 102.33% year-over-year to $54536.0; the TTM figure through Dec 2023 stood at $75199.0 (up 103.27% YoY), while the FY2025 annual figure was $11000.0, changed N/A from the prior year.
• Cash from Investing Activities came in at $54536.0 for Q4 2023 at Pasithea Therapeutics, up from $50159.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $70121.0 in Q2 2022 to a low of -$2.3 million in Q4 2022.
• A 3-year average of -$248603.7 and a median of -$1951.0 in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 18007.96% in 2022 and surged 293.16% in 2023, its largest moves.
• Pasithea Therapeutics' Cash from Investing Activities stood at -$12933.0 in 2021, then tumbled by 18007.96% to -$2.3 million in 2022, then soared by 102.33% to $54536.0 in 2023.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $54536.0, $50159.0, and $24392.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.

Peer Comparison